Sam Chun Dang Pharm said on the 22nd that it signed a joint development and commercialization partnership with Daiichi Sankyo Espha for sales of oral semaglutide in Japan. Daiichi Sankyo Espha was a subsidiary in charge of the Daiichi Sankyo Group's generics business and is now a separate entity sold to QOL Holdings.
The products for sale are generic versions of Rybelsus, an oral GLP-1 receptor agonist developed by Novo Nordisk, in 3 mg, 7 mg, and 14 mg, and oral Wegovy generics in 1.5 mg, 4 mg, 9 mg, 25 mg, and 50 mg.
The company added that the upfront payment, milestones, and revenue-sharing ratios will be announced after signing an amended agreement once the Japanese marketing authorization and price for the original oral Wegovy are determined.